Clinically relevant genes and regulatory pathways associated with NRAS(Q61) mutations in melanoma through an integrative genomics approach

Therapies such as BRAF inhibitors have become standard treatment for melanoma patients whose tumors harbor activating BRAF(V600) mutations. However, analogous therapies for inhibiting NRAS mutant signaling have not yet been well established. In this study, we performed an integrative analysis of DNA...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Wei, Jia, Peilin, Hutchinson, Katherine E., Johnson, Douglas B., Sosman, Jeffrey A., Zhao, Zhongming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4385866/
https://www.ncbi.nlm.nih.gov/pubmed/25537510

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4385866/
https://www.ncbi.nlm.nih.gov/pubmed/25537510

Ejemplares similares